Wesana Health has announced that they have received a positive written response from the Food and Drug Administration (FDA) regarding their pre-Investigational New Drug (IND) meeting for the novel therapy and proprietary protocol of SANA-013 for the treatment of Traumatic Brain Injury (TBI) related major depressive disorder (MDD).
Category Press Release
Published in Wesana Health
Companies Featured
Wesana HealthWesana Health is a data-driven life science company focused on the delivery and development of therapies, including psychedelics, to treat traumatic brain injury (TBI), migraines, depression and anxiety.